|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UBXN2B |
Gene summary for UBXN2B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UBXN2B | Gene ID | 137886 |
| Gene name | UBX domain protein 2B | |
| Gene Alias | p37 | |
| Cytomap | 8q12.1 | |
| Gene Type | protein-coding | GO ID | GO:0000045 | UniProtAcc | Q14CS0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 137886 | UBXN2B | LZE4T | Human | Esophagus | ESCC | 3.23e-04 | 1.57e-01 | 0.0811 |
| 137886 | UBXN2B | LZE20T | Human | Esophagus | ESCC | 1.73e-06 | 1.30e-01 | 0.0662 |
| 137886 | UBXN2B | LZE24T | Human | Esophagus | ESCC | 3.92e-05 | 1.73e-01 | 0.0596 |
| 137886 | UBXN2B | P1T-E | Human | Esophagus | ESCC | 1.26e-02 | 1.19e-01 | 0.0875 |
| 137886 | UBXN2B | P2T-E | Human | Esophagus | ESCC | 7.97e-15 | 2.33e-01 | 0.1177 |
| 137886 | UBXN2B | P4T-E | Human | Esophagus | ESCC | 1.18e-14 | 2.88e-01 | 0.1323 |
| 137886 | UBXN2B | P5T-E | Human | Esophagus | ESCC | 7.89e-06 | 1.52e-01 | 0.1327 |
| 137886 | UBXN2B | P8T-E | Human | Esophagus | ESCC | 4.58e-04 | 1.38e-01 | 0.0889 |
| 137886 | UBXN2B | P9T-E | Human | Esophagus | ESCC | 5.37e-06 | 8.99e-02 | 0.1131 |
| 137886 | UBXN2B | P10T-E | Human | Esophagus | ESCC | 1.18e-09 | 1.71e-01 | 0.116 |
| 137886 | UBXN2B | P11T-E | Human | Esophagus | ESCC | 1.51e-02 | 1.91e-01 | 0.1426 |
| 137886 | UBXN2B | P12T-E | Human | Esophagus | ESCC | 5.11e-11 | 2.14e-01 | 0.1122 |
| 137886 | UBXN2B | P15T-E | Human | Esophagus | ESCC | 2.94e-07 | 1.52e-01 | 0.1149 |
| 137886 | UBXN2B | P16T-E | Human | Esophagus | ESCC | 2.94e-25 | 4.42e-01 | 0.1153 |
| 137886 | UBXN2B | P17T-E | Human | Esophagus | ESCC | 5.29e-06 | 2.69e-01 | 0.1278 |
| 137886 | UBXN2B | P20T-E | Human | Esophagus | ESCC | 1.10e-12 | 2.45e-01 | 0.1124 |
| 137886 | UBXN2B | P21T-E | Human | Esophagus | ESCC | 5.24e-14 | 2.17e-01 | 0.1617 |
| 137886 | UBXN2B | P22T-E | Human | Esophagus | ESCC | 5.88e-08 | 3.94e-02 | 0.1236 |
| 137886 | UBXN2B | P23T-E | Human | Esophagus | ESCC | 3.28e-09 | 1.54e-01 | 0.108 |
| 137886 | UBXN2B | P24T-E | Human | Esophagus | ESCC | 1.03e-09 | 1.75e-01 | 0.1287 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
| GO:0043161111 | Esophagus | ESCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 312/8552 | 412/18723 | 3.53e-36 | 4.48e-33 | 312 |
| GO:014001414 | Esophagus | ESCC | mitotic nuclear division | 218/8552 | 287/18723 | 6.17e-26 | 1.78e-23 | 218 |
| GO:001623617 | Esophagus | ESCC | macroautophagy | 216/8552 | 291/18723 | 1.94e-23 | 4.57e-21 | 216 |
| GO:005165617 | Esophagus | ESCC | establishment of organelle localization | 273/8552 | 390/18723 | 9.13e-23 | 1.81e-20 | 273 |
| GO:190285015 | Esophagus | ESCC | microtubule cytoskeleton organization involved in mitosis | 116/8552 | 147/18723 | 1.25e-16 | 9.91e-15 | 116 |
| GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
| GO:000703314 | Esophagus | ESCC | vacuole organization | 127/8552 | 180/18723 | 1.04e-11 | 3.85e-10 | 127 |
| GO:00002802 | Esophagus | ESCC | nuclear division | 270/8552 | 439/18723 | 1.17e-11 | 4.24e-10 | 270 |
| GO:000699713 | Esophagus | ESCC | nucleus organization | 96/8552 | 133/18723 | 4.66e-10 | 1.21e-08 | 96 |
| GO:004578710 | Esophagus | ESCC | positive regulation of cell cycle | 196/8552 | 313/18723 | 9.27e-10 | 2.24e-08 | 196 |
| GO:000716320 | Esophagus | ESCC | establishment or maintenance of cell polarity | 143/8552 | 218/18723 | 2.05e-09 | 4.65e-08 | 143 |
| GO:000699811 | Esophagus | ESCC | nuclear envelope organization | 39/8552 | 47/18723 | 1.48e-07 | 2.35e-06 | 39 |
| GO:003001018 | Esophagus | ESCC | establishment of cell polarity | 96/8552 | 143/18723 | 1.69e-07 | 2.67e-06 | 96 |
| GO:190503712 | Esophagus | ESCC | autophagosome organization | 73/8552 | 103/18723 | 1.88e-07 | 2.93e-06 | 73 |
| GO:00726985 | Esophagus | ESCC | protein localization to microtubule cytoskeleton | 43/8552 | 54/18723 | 3.28e-07 | 4.61e-06 | 43 |
| GO:007176312 | Esophagus | ESCC | nuclear membrane organization | 29/8552 | 33/18723 | 5.30e-07 | 7.04e-06 | 29 |
| GO:00443804 | Esophagus | ESCC | protein localization to cytoskeleton | 45/8552 | 58/18723 | 6.89e-07 | 8.99e-06 | 45 |
| GO:000004513 | Esophagus | ESCC | autophagosome assembly | 69/8552 | 99/18723 | 1.10e-06 | 1.38e-05 | 69 |
| GO:00070308 | Esophagus | ESCC | Golgi organization | 101/8552 | 157/18723 | 1.78e-06 | 2.10e-05 | 101 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UBXN2B | SNV | Missense_Mutation | c.754N>A | p.Asp252Asn | p.D252N | Q14CS0 | protein_coding | deleterious(0.02) | possibly_damaging(0.657) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| UBXN2B | SNV | Missense_Mutation | rs747002448 | c.626N>C | p.Arg209Thr | p.R209T | Q14CS0 | protein_coding | deleterious(0) | possibly_damaging(0.721) | TCGA-D8-A27F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD |
| UBXN2B | SNV | Missense_Mutation | c.356N>A | p.Gly119Glu | p.G119E | Q14CS0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EA-A3QE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| UBXN2B | SNV | Missense_Mutation | c.847C>T | p.Arg283Trp | p.R283W | Q14CS0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| UBXN2B | SNV | Missense_Mutation | novel | c.560N>G | p.Leu187Arg | p.L187R | Q14CS0 | protein_coding | tolerated(0.82) | benign(0.223) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| UBXN2B | SNV | Missense_Mutation | c.776N>A | p.Ile259Asn | p.I259N | Q14CS0 | protein_coding | deleterious(0) | possibly_damaging(0.908) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| UBXN2B | SNV | Missense_Mutation | novel | c.497C>T | p.Pro166Leu | p.P166L | Q14CS0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| UBXN2B | SNV | Missense_Mutation | c.731N>G | p.Leu244Arg | p.L244R | Q14CS0 | protein_coding | tolerated(0.39) | possibly_damaging(0.467) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| UBXN2B | SNV | Missense_Mutation | rs765005760 | c.385N>T | p.Arg129Trp | p.R129W | Q14CS0 | protein_coding | deleterious(0.01) | benign(0.425) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| UBXN2B | SNV | Missense_Mutation | c.242N>T | p.Thr81Ile | p.T81I | Q14CS0 | protein_coding | tolerated(0.09) | benign(0.143) | TCGA-AP-A0LE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |